-
Je něco špatně v tomto záznamu ?
The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
Z. Huskova, J. Knillova, Z. Kolar, J. Vrbkova, M. Kral, J. Bouchal
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
15-28628A
Ministerstvo Zdravotnictví Ceské Republiky
DRO (FNOl, 00098892)
Ministerstvo Zdravotnictví Ceské Republiky
NV15-28628A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Directory of Open Access Journals
od 2013
PubMed Central
od 2013
Europe PubMed Central
od 2013
ProQuest Central
od 2013-01-01
Open Access Digital Library
od 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2013
- MeSH
- analýza moči metody MeSH
- biopsie MeSH
- časná detekce nádoru metody MeSH
- hyperplazie prostaty MeSH
- lidé MeSH
- nádorové biomarkery * moč MeSH
- nádory prostaty * diagnóza MeSH
- prostatický specifický antigen moč MeSH
- zánět MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5-10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21027859
- 003
- CZ-PrNML
- 005
- 20230117103258.0
- 007
- ta
- 008
- 211103s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/biomedicines8060173 $2 doi
- 035 __
- $a (PubMed)32630458
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Huskova, Zlata $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic
- 245 14
- $a The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy / $c Z. Huskova, J. Knillova, Z. Kolar, J. Vrbkova, M. Kral, J. Bouchal
- 520 9_
- $a The main advantage of urinary biomarkers is their noninvasive character and the ability to detect multifocal prostate cancer (CaP). We have previously implemented a quadruplex assay of urinary markers into clinical practice (PCA3, AMACR, TRPM8 and MSMB with KLK3 normalization). In this study, we aimed to validate it in a larger cohort with serum PSA 2.5-10 ng/mL and test other selected transcripts and clinical parameters, including the percentage of free prostate-specific antigen (PSA) (% free PSA) and inflammation. In the main cohort of 299 men, we tested the quadruplex transcripts. In a subset of 146 men, we analyzed additional transcripts (CD45, EPCAM, EZH2, Ki67, PA2G4, PSGR, RHOA and TBP). After a prostate massage, the urine was collected, RNA isolated from a cell sediment and qRT-PCR performed. Ct values of KLK3 (i.e., PSA) were strongly correlated with Ct values of other genes which play a role in CaP (i.e., PCA3, AMACR, TRPM8, MSMB and PSGR). AMACR, PCA3, TRPM8 and EZH2 mRNA expression, as well as % free PSA, were significantly different for BPH and CaP. The best combined model (% free PSA plus PCA3 and AMACR) achieved an AUC of 0.728 in the main cohort. In the subset of patients, the best AUC 0.753 was achieved for the combination of PCA3, % free PSA, EPCAM and PSGR. PCA3 mRNA was increased in patients with inflammation, however, this did not affect the stratification of patients indicated for prostate biopsy. In conclusion, the percentage of free PSA and urinary markers contribute to a more accurate indication for prostate biopsy.
- 650 17
- $a nádory prostaty $x diagnóza $7 D011471 $2 czmesh
- 650 _7
- $a hyperplazie prostaty $7 D011470 $2 czmesh
- 650 _7
- $a časná detekce nádoru $x metody $7 D055088 $2 czmesh
- 650 17
- $a nádorové biomarkery $x moč $7 D014408 $2 czmesh
- 650 _7
- $a biopsie $7 D001706 $2 czmesh
- 650 _7
- $a prostatický specifický antigen $x moč $7 D017430 $2 czmesh
- 650 _7
- $a zánět $7 D007249 $2 czmesh
- 650 _7
- $a analýza moči $x metody $7 D016482 $2 czmesh
- 650 _7
- $a lidé $7 D006801 $2 czmesh
- 650 _7
- $a mužské pohlaví $7 D008297 $2 czmesh
- 655 _2
- $a časopisecké články $7 D016428
- 655 _7
- $a práce podpořená grantem $7 D013485 $2 czmesh
- 700 1_
- $a Knillová, Jana $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic $7 xx0098127
- 700 1_
- $a Kolář, Zdeněk, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic $d 1953- $7 jn20000710256
- 700 1_
- $a Vrbková, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic $7 _AN085567
- 700 1_
- $a Král, Milan $u Department of Urology, University Hospital, 779 00 Olomouc, Czech Republic $7 xx0079094
- 700 1_
- $a Bouchal, Jan, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 779 00 Olomouc, Czech Republic $d 1973- $7 xx0034399
- 773 0_
- $w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 8, č. 6 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32630458 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211103 $b ABA008
- 991 __
- $a 20230117103254 $b ABA008
- 999 __
- $a kom $b bmc $g 1718483 $s 1148390
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 8 $c 6 $e 20200625 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
- GRA __
- $a 15-28628A $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a DRO (FNOl, 00098892) $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a NV15-28628A $p MZ0
- LZP __
- $c NLK120 $d 20230117 $a 2021-granty